Bavarian Nordic options Prostvac to BMS; option exercise unlikely
Executive Summary
Bristol-Myers Squibb Co. received an option to exclusively license Bavarian Nordic AS's Phase III Prostvac (rilimogene galvacirepvec), a vaccine for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Immuno-Oncology
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice